The role of pfmdr1 in Plasmodium falciparum tolerance to artemether‐lumefantrine in Africa
Open Access
- 5 June 2007
- journal article
- Published by Wiley in Tropical Medicine & International Health
- Vol. 12 (6) , 736-742
Abstract
Summary: Objective Artemether‐lumefantrine (AL), presently the most favoured combination therapy against uncomplicated Plasmodium falciparum malaria in Africa, has recently shown to select for the pfmdr1 86N allele. The objective of this study was to search for the selection of other mutations potentially involved in artemether‐lumefantrine tolerance and/or resistance, i.e. pfmdr1 gene amplification, pfmdr1 Y184F, S1034C, N1042D, D1246Y, pfcrt S163R and PfATP6 S769N.Methods The above mentioned SNPs were analysed by PCR–restriction fragment length polymorphism and pfmdr1 gene amplification by real‐time PCR based protocols in parasites from 200 children treated with AL for uncomplicated P. falciparum malaria in Zanzibar.Results A statistically significant selection of pfmdr1 184F mostly in combination with 86N was seen in reinfections after treatment. No pfmdr1 gene amplification was found.Conclusion The results suggest that different pfmdr1 alleles are involved in the development of tolerance/resistance to lumefantrine.Keywords
This publication has 22 references indexed in Scilit:
- Amodiaquine resistance is not related to rare findings of pfmdr1 gene amplifications in KenyaTropical Medicine & International Health, 2006
- Molecular genotyping to distinguish between recrudescents and new infections in treatment trials of Plasmodium falciparum malaria conducted in Sub-Saharan Africa: adjustment of parasitological outcomes and assessment of genotyping effectivenessTropical Medicine & International Health, 2006
- Molecular and Pharmacological Determinants of the Therapeutic Response to Artemether-Lumefantrine in Multidrug-Resistant Plasmodium falciparum MalariaClinical Infectious Diseases, 2006
- Selection of Plasmodium falciparum pfmdr1 Alleles following Therapy with Artemether-Lumefantrine in an Area of Uganda where Malaria Is Highly EndemicAntimicrobial Agents and Chemotherapy, 2006
- Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6The Lancet, 2005
- Amplification ofPlasmodium falciparumMultidrug Resistance Gene 1 in Isolates from GabonThe Journal of Infectious Diseases, 2005
- Efficacy of Artesunate Plus Amodiaquine versus That of Artemether-Lumefantrine for the Treatment of Uncomplicated Childhood Plasmodium falciparum Malaria in Zanzibar, TanzaniaClinical Infectious Diseases, 2005
- Coartem (Artemether‐Lumefantrine) in Africa: The Beginning of the End?The Journal of Infectious Diseases, 2005
- In Vivo Selection ofPlasmodium falciparum pfmdr186N Coding Alleles by Artemether‐Lumefantrine (Coartem)The Journal of Infectious Diseases, 2005
- Analysis of pfmdr1 and drug susceptibility in fresh isolates of Plasmodium falciparum from Subsaharan AfricaMolecular and Biochemical Parasitology, 1995